Efficacy and Safety of Losartan in Children With Ig A Nephropathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2017-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators hypothesize that using Losartan would help decrease proteinuria in controlling proteinuria in children with immunoglobulin A nephropathy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Registry of IgA Nephropathy in Chinese Children

NCT03015974

IgA Nephropathy Proteinuria in Nephrotic Range Immunosuppressive Treatment

RECRUITING

The Research of Standard Diagnosis and Treatment for HSPN With Mild Proteinuria in Children

NCT02532790

Henoch-Schoenlein Purpura Nephritis

UNKNOWN PHASE2

Effect of Immunosuppression in IgA Nephropathy

NCT03468972

Biopsy-proven IgA Nephropathy

UNKNOWN PHASE4

A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence

NCT07087314

Nephrotic Syndrome in Children

RECRUITING PHASE2

The Research of Standard Diagnosis and Treatment for HSPN in Children

NCT02532777

Henoch-Schoenlein Purpura Nephritis

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Twenty nine patient with IgA nephropathy with proteinuria (urine protein to creatinine ratio \> 0.3 mg/mg) were included in the study. All patients had received losartan treatment for 24 weeks. Changes in blood pressure, proteinuria, renal function, and biochemical parameters were prospectively evaluated before and at 4 weeks and 24 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glomerulonephritis, IGA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Losartan treatement

All patients had received losartan treatment for 24 weeks.

Group Type EXPERIMENTAL

Losartan

Intervention Type DRUG

Dose of Losartan : 0.7mg/kg once daily.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Losartan

Dose of Losartan : 0.7mg/kg once daily.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cozaar

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: 2years or older and younger than 18 years
* Biopsy-proven Ig A Nephropathy
* Estimated GFR ≥ 90mL/min/m\^2
* Mean urinary protein-creatinine ratio \> 0.3 g/g from three first-morning spot urine collections